Formulation Development
FORMULATION DEVELOPMENT WHITE PAPERS & ARTICLES
-
Past, Present And Future Of Digital PCR
Move beyond relative quantification to achieve absolute precision. Learn how partitioning technology overcomes traditional limitations to deliver reproducible gene expression data for rare targets.
-
PCR Assays Capture Gene Expression Insights
Move beyond relative quantification to achieve absolute precision. Learn how partitioning technology overcomes qPCR limitations to deliver reproducible gene expression data for rare targets.
-
Silencing CDMO Project Noise: The Power Of Low-Drama Drug Development
Move beyond reactive firefighting by prioritizing disciplined leadership and data-driven milestones. The winning model for complex programs is focused, high-maturity, low-drama execution.
-
Navigating Nitrosamine Impurities In Pharmaceutical Drug Development
Understanding formation mechanisms and potency categorization allows developers to mitigate risks early, ensuring regulatory compliance and patient safety without compromising product performance.
-
Nasal Delivery: Strategies For Success
A strengthened partnership enhances manufacturing for an ultra‑rare disease therapy, leveraging advanced containment upgrades to improve safety, reliability, capacity, and maintain global patient access.
FORMULATION DEVELOPMENT APPLICATIONS & STUDIES
-
Assessing The Success Of CRISPR Gene Therapies Using ddPCR Technology
Achieve high-fidelity results in gene therapy research. Discover how absolute quantification overcomes traditional limitations to provide the precision needed for validating CRISPR edits.
-
Ultra-Low Cross-Linked Microgel Purification
ULC microgel purification is often slowed by linear polymer contamination and limitations of centrifugation. Explore how hollow fiber TFF improves filtration efficiency and supports scalable processing.
-
mRNA Manufacturing With Fed-Batch In Vitro Transcription
A milliliter-scale approach to IVT optimization reveals how controlled feeding, precise pH management, and real-time monitoring can boost mRNA yield and streamline scale-up to larger bioreactor volumes.
-
Development Of A Non-Standard Protein Therapeutic
Discover how a tailored development approach transformed a complex therapeutic protein into a candidate ready for early-stage clinical trials.
-
MicroCoat™ Technology DFor Taste-Masking Amodiaquine, Artesunate In Oral Antimalarial Formulations
Drive forward the development and adoption of taste‑masked ASAQ micropellets so children in low‑resource settings can receive life‑saving antimalarial treatment that is both effective and easy to take.
FORMULATION DEVELOPMENT SOLUTIONS
- MaxPeak Premier Columns For Peptide Analysis
- Unlock Amorphous Solubility Enhancement For Challenging Compounds
- Microcalorimetry: RS-DSC, DSC & ITC
- A High-Purity Excipient Suitable For High-Risk Vaccine Applications
- Contract Manufacturing Solutions For Drug Delivery Systems
- Gibco Efficient-Pro Medium And Feeds Evaluation Guide
- Our Science-Forward Approach To API Development, Manufacturing
- Complete Organ-Chip Solutions To Fast-Track Your Drug Discovery
- How Product Quality Translates To Better Results
- Comprehensive Support For Regulated Laboratories With FlexCHOICE Service Coverage
PHARMACEUTICAL AND FORMULATION DEVELOPMENT NEWS
- Strategic Oral Solid Dose Facility Investment In Ireland Expands Novo Nordisk's Global Manufacturing Footprint
- Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas
- Quotient Sciences Extends Commercial Manufacturing Partnership For Ultra-Rare Disease Treatment
- Bora Pharmaceuticals And GSK Sign $250M Five Year Global Manufacturing Contract
- AbbVie Announces $380 Million Investment With Two New Active Pharmaceutical Ingredient Manufacturing Facilities In Illinois
- Johnson & Johnson Announces $1 Billion Investment With New Cell Therapy Manufacturing Facility In Pennsylvania
- Esco Philippines Returns To The 41st PSNM Annual Convention: Supporting Innovation In Nuclear Medicine
- Syntegon Launches AIM9 High-Speed Inspection Platform
- JHS CEO Chris Preti Receives 2026 Person Of Influence Award
- Subcutaneously Administered Nanotrastuzumab Matches Performance Of Herceptin HYLECTA In Minipig Study